LONDONÂ and NEW YORK
 , May 12, 2021 /PRNewswire/  Huma Therapeutics Limited today announces the completion of its latest funding round with financing of approximately $130 million. The investment will scale Huma s modular platform which can power digital hospitals at home nationally, and support the pharmaceutical and research industries to run the largest ever decentralized clinical trials. Huma s platform combines predictive algorithms, digital biomarkers and real-world data to advance proactive care and research.
Leaps by Bayer and Hitachi Ventures led the Series C funding round, which also saw new strategic and financial investors become shareholders. Samsung Next, Sony Innovation Fund by IGV , Unilever Ventures and HAT Technology & Innovation Fund by HAT, as well as individuals Nikesh Arora (former president of SoftBank) and Michael Diekmann (Chairman of Allianz) are also new shareholders.
Monitoring and Evaluation Consultancy in Viet Nam about Protection and Human Rights, requiring 10+ years of experience, from SI; closing on 07 Mar 2021
Monitoring and Evaluation Consultancy in Viet Nam about Protection and Human Rights, requiring 5-9 years of experience, from SI; closing on 07 Mar 2021
Monitoring and Evaluation Consultancy in Viet Nam about Protection and Human Rights, requiring 5-9 years of experience, from SI; closing on 07 Mar 2021
Monitoring and Evaluation Consultancy in Viet Nam about Protection and Human Rights, requiring 10+ years of experience, from SI; closing on 07 Mar 2021